Avecho Biotechnology Limited · ASX:AVE
Avecho Biotechnology — Investor Presentation (January 2021)
27 slides from Avecho Biotechnology's investor presentation, January 2021
Slide 1: Avecho Update
Avecho Update January 2021 www.avecho.com.au | ASX:AVE
Slide 2: Safe Harbour Statement
Safe Harbour Statement This presentation, and any representations made before, during or after the presentation, may include forward- looking statements that are inherently subject to risks and uncertainties. These statements relate to, but are not limited to: (1) the safety or efficacy of, or poten
Slide 3: Company Snapshot
Company Snapshot Shares 1,598M Avecho – YTD price and volume Market cap $43.2M * ***** * * * * * * * * * ** ** 0.009 Options 87.6M 0.008 0.007 Cash 1 $2.64M 0.006 Last qtr gross burn 1 ($0.5M) 0.005 0.004 0.003 Headquarters Melbourne 0.002 Board Greg Collier (Chair) 0.001 Ross Murdoch (NED) David Se
Slide 4: Avecho Management & Board
Avecho Management & Board Dr Paul Gavin Dr Roksan Libinaki Melanie Leydin Chief Executive Officer Chief Operating Officer CFO and Company Secretary − 18yrs Avecho − 18yrs Avecho − 23yrs accounting − pharma development − animal health development − Inst. of Chartered Accts − TPM ® inventor − TPM® man
Slide 5: Overview of Avecho's TPM® technology
Overview of Avecho’s TPM® technology TPM® is a proprietary combination of two forms of phosphorylated vitamin E Propofol TPM® TPM® is a unique excipient that encapsulates drug molecules TPM® has been used to formulate drugs to improve their: - solubility - stability - oral bioavailability - transder
Slide 6: Strategic Focus
Strategic Focus Avecho has a clear, strategic focus to deliver on two fronts: Realise value from its portfolio of existing human Leverage its proprietary TPM® platform to develop and animal health assets new cannabinoid-based pharmaceuticals • Minimal investment going forward • TPM® is ideal for for
Slide 7: Human and Animal Health
i\vecho Human and Animal Health
Slide 8: Overview of Human Health Assets
Overview of Human Health Assets Human health assets Priority Prospective Priority products for licensing with the aim to Assets ready for ongoing business development secure a commercial deal for 1 or more of these effort and presentation to potential partners over products over the next 12 months t
Slide 9: Daptomycin TPM® - Partnering Opportunity
Daptomycin TPM® - Partnering Opportunity Daptomycin is an antibiotic that became generic in 2016 which is used for the treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) US sales of daptomycin were US$700M in 2018 with $465M coming from the sale of generics ($205M Teva, $180M Fresenius,
Slide 10: Propofol TPM® - Partnering Opportunity
Propofol TPM® - Partnering Opportunity Propofol is an intravenous anaesthetic used for general anaesthesia in surgical patients, with a global market of ~$1Bn USD Propofol is an oil which has been formulated as an opaque emulsion comprising of 1% drug in 10% soya oil plus water While effective as an
Slide 11: Vitamin K TPM® - Partnering Opportunity
Vitamin K TPM® - Partnering Opportunity Vitamin K is an essential factor required for blood clotting and is administered to: - all newborns to prevent vitamin K bleeding deficiency (VKBD) - adults with coagulation disorders resulting from vitamin K deficiency or interference Global sales of Vitamin
Slide 12: Other Human Health Assets – Partnering Opportunities
Other Human Health Assets – Partnering Opportunities Product Opportunity Status Oxycodone TPM® patch Transdermal patch providing sustained Steps required for US filing established pain relief with reduced side effects Oxymorphone TPM® patch Transdermal patch sustained pain relief Pre-IND meeting wit
Slide 13: Animal Health
Animal Health TPM® has shown promise as an additive to feedstock: - improves feed efficiency for faster weight gain and stock turnover - improves meat quality and potential shelf life - can improve animal health and disease resistance - is a non-antibiotic alternative to banned antibiotic growth pro
Slide 14: Cannabinoid Pharmaceuticals
Cannabinoid Pharmaceuticals
Slide 15: Cannabinoid-based Pharmaceuticals
Cannabinoid-based Pharmaceuticals In the past decade, there has been a transformational shift resulting from a recognition of the therapeutic potential of cannabis and cannabis extracts The majority of countries around the world have recently enacted legalisation permitting the use of cannabis extra
Slide 16: Potential use in multiple therapeutic areas
Potential use in multiple therapeutic areas Data from available clinical studies supports the use of cannabinoids for a range of different medical conditions Conclusive or substantial evidence - chronic pain - chemo-induced nausea and vomiting - multiple sclerosis spasticity - treatment-resistant se
Slide 17: Growing market for therapeutic uses of cannabis
Growing market for therapeutic uses of cannabis • In more mature markets (Canada, Colorado Australian approvals for medicinal cannabis prescriptions2 and California), around 1-2% of the population 10,000 45,000 use cannabis products for therapeutic purposes 9,000 40,000 • In Australia, this would eq
Slide 18: Medical market likely to focus on pharmaceutical products
Medical market likely to focus on pharmaceutical products Pharmaceutically developed products are expected to dominate the medical cannabis market in the long term: - standardised pharmaceutical delivery formats - clinical safety and efficacy data - registered products are physician preferred Patien
Slide 19: TPM® is ideal for pharmaceutical formulation of cannabinoids
TPM® is ideal for pharmaceutical formulation of cannabinoids Cannabinoids (the key active compounds in cannabis) are oil soluble molecules with low solubility in water Oil soluble molecules have poor oral bioavailability, which is also true for cannabinoids (3-8% absorbed) This presents challenges f
Slide 20: Focus is on developing pharmaceutical cannabinoid products
Focus is on developing pharmaceutical cannabinoid products Avecho intends to use TPM® to develop cannabinoid-based pharmaceuticals: - with known and consistent dosing - delivered in a familiar, pharmaceutical format - backed by robust clinical evidence - able to be manufactured at scale Taking a pha
Slide 21: Plan for developing TPM® formulation of cannabinoids
Plan for developing TPM® formulation of cannabinoids PROOF OF FORMULATION PRECLINICAL CLINICAL CONCEPT DEVELOPMENT STUDIES STUDIES COMPLETED COMPLETED COMPLETING 2021 Demonstrated that TPM® Demonstrated that TPM® Animal studies Human safety, can improve the solubility formulations can improve demons
Slide 22: TPM® formulations increase oral bioavailability of CBD
TPM® formulations increase oral bioavailability of CBD Research conducted at Bioneer:FARMA in Copenhagen Total CBD absorbed (AUC) Rats received a single oral dose of CBD and drug content measured in the blood over time. Absorption from TPM® formulations compared against CBD in MCT (as sold to patien
Slide 23: Confirmed increase in bioavailability leads to…
Confirmed increase in bioavailability leads to… Greater therapeutic effect New indications, previously untreatable because of high doses required Reduced dosing for increased patient safety Reduced dosing for cost savings to patients Less variability between doses; patient/physician prefer
Slide 24: Cannabinoid clinical trials to begin Q1 2021
Cannabinoid clinical trials to begin Q1 2021 Two parallel trials to support the development of the pharmaceutical product, and licensing/sales through SAS-B Phase I Clinical Trial Observational Clinical Trial • Characterises delivery profile from product • Real world customer feedback on product • D
Slide 25: 12 Month News flow communicated in June
12 Month News flow communicated in June Initial cannabinoid formulation development with TPM® Preclinical studies evaluating TPM® cannabinoids First-in-man studies using TPM®-formulated cannabinoids Disease-specific clinical trials using TPM®-cannabinoids Commercial licence or sale of one or more hu
Slide 26: Avecho is an exciting investment opportunity
Avecho is an exciting investment opportunity • Attractive valuation: Valued like a start-up, but ~20 years of R&D and multiple, licensable assets • Multiple pharmaceutical assets currently the focus of a BD campaign. Opportunity for multiple deals • Enhanced cannabinoid products with demonstrated ad
Slide 27: Contact
Contact Dr Paul Gavin Chief Executive Officer +61 3 9002 5000 pgavin@avecho.com.au Melbourne Office Unit A8, 2A Westall Road Hallmarc Business Park Clayton VIC 3168 Australia Tel: +61 3 9002 5000 Email: info@avecho.com.au 27
Avecho Biotechnology — Investor Presentation (January 2021) on 6ix